Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Doubl...
Iain McInnes, Jaclyn K Anderson, Marina Magrey et. al.

Nov 9th, 2020 - Background/Purpose: Upadacitinib (UPA), an oral, reversible, JAK inhibitor approved to treat rheumatoid arthritis (RA), is under evaluation for psoriatic arthritis (PsA). We assess efficacy and safety of UPA vs placebo (PBO) and adalimumab (ADA) in patients (pts) with PsA and prior IR or intolerance to ≥1 non-biologic DMARD (non-bDMARD). Methods: Pts with active PsA (≥3 swollen and ≥3 tender jo...

Abnormal DNA Methylation in CD4+T Cells Is Associated with Cardiovascular Risk in Psoriatic Arthritis
Iván Arias de la Rosa, Maria Dolores Lopez-Montilla, Carlos Pérez-Sánchez et. al.

Nov 9th, 2020 - Background/Purpose: Cardiovascular risk factors are increased in Psoriatic Arthritis (PsA). Latest studies suggested that inflammatory and metabolic disorders may be under epigenetic control, including DNA methylation. DNA methylation is an unexplored area in the field of PsA. Objective: To study the alterations in the genome-wide DNA methylation profile of CD4+T cells from PsA patients and its...

An Integrative Approach to Identify Heritable and De Novo Genomic Variations in Psoriatic Arthritis Mutilans and Understand Its Systems Biology
Sara Rahmati, Quan Li, Dafna Gladman et. al.

Nov 9th, 2020 - Background/Purpose: Psoriasis is a chronic autoimmune skin disease that burdens ~3% of North Americans. ~24% of psoriatic patients develop psoriasis arthritis (PsA), an inflammatory disease which is often progressive and in its extreme form, PsA mutilans, causes permanent joint damage and functional disability. PsA is highly heritable; ~40% of patients with PsA have at least one close relative ...

T Cells with IL-17A+ Signature in Psoriatic Arthritis Are of Different Subpopulations and Are Polyfuntional
Siba Raychaudhuri1 and Smriti Raychaudhuri, Division of Rheumatology, Allergy & Clinical Immunology et. al.

Nov 9th, 2020 - Background/Purpose: A variety of T cells such as Th1, Th2, Th9, Th17, NKT, MAIT, etc have been attributed to multiple autoimmune diseases.  In psoriatic arthritis (PsA) contributing role of the Th17 cells have been observed and lately success of IL17/IL-23 targeted therapies has further substantiated this. Here we will share our cumulative data on Th17 cells in PsA collected over last 2 decades...

Ultrasound Doppler Enthesitis Shows Sensitivity to Change After Biological Therapy in Spondyloarthritis and Psoriatic Arthritis Patients
Juan Molina Collada, Cristina Macía-Villa, Chamaida Plasencia et. al.

Nov 9th, 2020 - Background/Purpose: The assessment of activity in spondyloarthritis (SpA) and psoriatic arthritis (PsA) involves several domains, including enthesitis. Clinical enthesitis has shown low sensitivity, specificity and reliability. The MAdrid Sonographic Enthesitis Index (MASEI) is a feasible and reliable ultrasound score, but its responsiveness to treatment has not yet been evaluated. Our aim was ...

Ultrasound, Magnetic Resonance Imaging and Radiography of the Fingers’ Joints of Psoriatic Arthritis Patients
Ari Polachek, Victoria Furer, Mirna Zureik et. al.

Nov 9th, 2020 - Background/Purpose: Ultrasound (US), magnetic resonance imaging (MRI) and conventional radiography are the leading imaging modalities for musculoskeletal (MSK) assessment in PsA. However, little is reported about the discrepancies between these tools in PsA patients. The aim of this study is to examine the agreement between these modalities and to evaluate the sensitivity and specificity of US ...

Prevalence and Distribution of Peripheral Musculoskeletal Manifestations in Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis: Results of the International, Cross-sectio...
Clementina Lopez-Medina, Anna Molto, Joachim Sieper et. al.

Nov 9th, 2020 - Background/Purpose: Peripheral musculoskeletal manifestations in patients with Psoriatic Arthritis (PsA) have been widely studied. However, there is a lack of knowledge on the distribution of such manifestations in the whole group of spondyloarthritis (SpA) and specifically in axial SpA (axSpA), even though an important overlap exists between SpA subtypes and PsA. The ASAS-PerSpA study aimed to...

Efficacy and Safety of Tildrakizumab, a High-Affinity Anti–Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Mult...
Philip Mease, Saima Chohan, Ferran J. García Fructuoso et. al.

Nov 9th, 2020 - Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate to severe plaque psoriasis.1 The efficacy and safety of TIL up to week (W)52 in patients with psoriatic arthritis (PsA) was evaluated in a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study (NCT02980692). Methods: Patients (pts) ≥18 years wi...

NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis
Siba Raychaudhuri1 and Smriti Raychaudhuri, UC Davis, School of Medicine et. al.

Nov 9th, 2020 - Background/Purpose: Function of Nerve Growth Factor (NGF) in the nervous system and its regulatory role in pain is well defined. We have shown earlier that NGF levels are increased in synovial fluid (SF) from psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients (Raychaudhuri SP, eta al. Arthritis Rheum. 2011;63:3243-52) Here we are providing defined mechanism(s) through which NGF ac...

Maternal and Fetal Outcomes in Pregnant Women with Psoriatic Arthritis: A Systematic Literature Review
Agna Neto, Rita Pinheiro Torres, Helena Donato et. al.

Nov 9th, 2020 - Background/Purpose: The onset of psoriatic arthritis (PsA) often occurs between the ages of 30 and 50 years. Accordingly, many female patients are diagnosed during childbearing age, potentially impacting their pregnancy outcomes. However, there is a paucity of data concerning the fetal and maternal outcomes in this population and most of the information is extrapolated from studies on rheumatoi...

Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis
Philip Mease, Désirée van der Heijde, Bruce Kirkham et. al.

Nov 9th, 2020 - Background/Purpose: Assessment of radiographic joint damage extent and progression is important in clinical trials evaluating treatments for psoriatic arthritis (PsA). Joint damage in patients with PsA has substantial impact on physical function, quality of life and survival, therefore, inhibiting radiographic progression is one of the main goals of therapy.1,2 Here we present results from a ma...

Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Clinical Remission Compared to Active Disease
Victoria Furer, Ari Polachek, David Levartovsky et. al.

Nov 9th, 2020 - Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) is based on tender and swollen joint counts (TJC and SJC, respectively). Yet, the prevalence of subclinical synovitis in patients in clinical remission is unknown. The purpose of this study is to estimate the MRI-detected prevalence and distribution of subclinical inflammatory changes of hands joints in patients wit...

The Reliability of Scoring Sonographic Entheseal Abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Lihi Eder, Sibel Aydin2 and Gurjit Kaeley, Women’s College Research Institute et. al.

Nov 9th, 2020 - Background/Purpose: DUET is a study supported by the Group for Assessment for Psoriasis and Psoriatic Arthritis (GRAPPA) that aims to develop a novel sonographic scoring system for enthesitis to assist with PsA diagnosis. The objectives of the present study are to define the elementary lesions of enthesitis for the DUET study and to assess the inter-rater reliability of the central readers in s...

The Association Between Imaging Sub-phenotypes of Psoriatic Arthritis and Gene Expression Profiles
Lihi Eder, Lee Quan, Sara Rahmati et. al.

Nov 9th, 2020 - Background/Purpose: Heterogeneity is a hallmark of psoriatic arthritis (PsA), which is reflected in diverse clinical, imaging and molecular features, various disease courses and treatment responses. We hypothesized that specific molecular markers underlie the various imaging manifestations of PsA. The study objective was to identify imaging sub-phenotypes in patients with PsA and determine thei...

Patients with Inflammatory Arthritis Who Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Smartphone Apps: A Cross-sectional Study of 101 Patients, the ImBAIA Study
Thomas Davergne, Rawdha Tekaya, Camille Deprouw et. al.

Nov 9th, 2020 - Background/Purpose: Adherence to both medications and physical activity is insufficient in patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA). Are there patterns towards adherence to both of these aspects of management? Objectives: to assess and compare adherence to medication and levels of physical activity colle...

Prevalence of Ultrasound Findings Suggestive of Inflammatory Arthritis in Children with Skin Psoriasis (ChildEchoPso)
Luis Coronel, Tania Gudu, Sophie Ruel-Gagné et. al.

Nov 9th, 2020 - Background/Purpose: The prevalence of psoriasis in children is estimated between 0.5-1% (1), and can be associated with musculoskeletal involvement, althought the prevalence and typology of such involvement is unknown. (2) Over the last years ultrasound associated with Doppler (PDUS) has become an important tool for evaluating joint involvement in children. Several studies have shown the high s...

Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-5...
Philip Mease, Philip Helliwell, Dafna Gladman et. al.

Nov 9th, 2020 - Background/Purpose: Guselkumab (GUS), an interleukin-23 inhibitor, improved axial symptoms of active psoriatic arthritis (PsA) through week 24 in a pooled analysis from two phase 3 trials (DISCOVER-1 and DISCOVER-2).1 We now report the efficacy of GUS through 1 year in PsA patients (pts) with imaging-confirmed sacroiliitis in DISCOVER-1&2. Methods: In DISCOVER-1, 381 pts with active PsA (≥ 3 sw...

Fertility and Pregnancy Outcomes in Women with Spondyloarthritis: A Systematic Review and Meta-analysis
Sabrina Hamroun, Aghilès Hamroun, Jean-Joël Bigna et. al.

Nov 9th, 2020 - Background/Purpose: Women with spondyloarthritis (SpA) are often affected by the disease during their reproductive years1. However, little is known about the impact of the disease and its treatments on fertility and pregnancy outcomes, as well as the effect of pregnancy itself on disease activity2. The aim of the study was to determine the effects of spondyloarthritis on fertility and pregnancy...

Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco, Ker-Ai Lee, Shadi Akhtari et. al.

Nov 8th, 2020 - Background/Purpose: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and troponin I (TnI) are established cardiac biomarkers that predict cardiovascular events (CVEs) and mortality in apparently healthy individuals and at-risk populations. While patients with psoriatic arthritis and psoriasis, collectively termed psoriatic disease (PsD), have an increased risk of developing CVEs, the u...

Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Laura Coates, Christopher Ritchlin, Laure Gossec et. al.

Nov 8th, 2020 - Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody that specifically binds to the p19-subunit of IL-23. GUS has demonstrated efficacy across the various manifestations of PsA including skin, joint, soft tissue and structural damage at Week24 (W24) of DISCOVER-11 and DISCOVER-22, Phase 3 trials of patients (pts) with active PsA. Here we assess GUS efficacy through W24 in both st...